Celltrion Inc.’s Truxima became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.

Roche is investigating a case of a German patient diagnosed with a deadly brain infection called PML after taking one dose of the company’s new MS drug Ocrevus.

November 5, 2015By Mark Terry, BioSpace.com Breaking News Staff   After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s strategy. On Oct. 21, 2015, Biogen released its third-quarter financials which included $2.8 billion in revenues, an 11 percent increase compared to the third quarter […]

PARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug with India-based Glenmark Pharmaceuticals.   During a second-quarter results analysis with media members, Glenmark revealed that Sanofi was terminating the development agreement for vatelizumab, also […]

Cambridge, Mass.-based Biogen, Inc. (BIIB) announced today that it was restructuring, cutting 11 percent of its workforce, and slashing programs. In addition, the company announced that its Phase III ASCEND clinical trial of natalizumab for the treatment of secondary progressive multiple sclerosis (SPMS) failed to hit its primary and secondary endpoints. As part of the […]

A Texas teenager who contracted a rare brain-eating disease after swimming in a lake about 70 miles (110 km) north of Houston has died, according to his family and local media. The 14-year-old Michael Riley Jr., a junior Olympian and honor student, seemed to have contracted the disease after he went swimming on Aug. 13 […]

The U.S. Food and Drug Administration said it will update the label of Novartis AG’s multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use. A case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported with the use of the drug, a first […]